Prospective Database for Prediction of Atrial Fibrillation in Pacemaker and ICD Patients
Launched by MEDICAL UNIVERSITY OF GRAZ · Nov 24, 2017
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a way to predict the occurrence of atrial fibrillation (AF) in patients who have a pacemaker or an implantable cardioverter defibrillator (ICD). Atrial fibrillation is a heart condition that can increase the risk of stroke, and the goal of this research is to develop a better method to foresee when AF might happen in individual patients. The study will involve 250 participants who have either a dual-chamber pacemaker or an ICD with an atrial lead. Researchers will collect health information and monitor heart rhythms using a special device called a Holter monitor for 24 hours. After six months, they will check the devices to see if AF occurred during this time. The data gathered will help create a prediction tool that could inform doctors about the need for treatments to prevent strokes.
To be eligible for this trial, participants should be between 65 and 74 years old and have a pacemaker or ICD that is working properly. They must have a specific score (called the CHADS-VASc score) indicating a higher risk for stroke and should not currently be experiencing AF or any issues with their devices. Participants can expect regular check-ins and monitoring of their heart rhythm, contributing to important research that may improve care for future patients. This trial is currently recruiting individuals of all genders who meet the criteria.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Implanted pacemaker or implanted cardioverter defibrillator (ICD) with atrial lead
- • CHADS-VASc Score of 2 or more
- • Sinus rhythm or atrial paced rhythm
- • Atrial stimulation rate 50% or less
- • ModeSwitch rate 50% or less since last pacemaker interrogation
- Exclusion Criteria:
- • pacemaker or ICD malfunction
- • atrial fibrillation (AF) at time of pacemaker / ICD interrogation
- • AF during 24-hour Holter ECG monitoring
- • permanent AF
About Medical University Of Graz
The Medical University of Graz, a leading institution in Austria, is dedicated to advancing medical knowledge and improving patient care through innovative research and clinical trials. Renowned for its interdisciplinary approach, the university collaborates with various healthcare professionals and researchers to explore cutting-edge therapies and treatments. With a commitment to ethical standards and patient safety, the Medical University of Graz actively contributes to the global medical community by facilitating rigorous clinical trials that aim to translate scientific discoveries into practical applications for improved health outcomes.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Graz, , Austria
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials